Intra-Cellular Therapies, Inc.
430 E 29th St Ste 900
New York
New York
10016
United States
Website: http://www.intracellulartherapies.com/
Email: info@intracellulartherapies.com
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies Inc. is a publicly traded biopharmaceutical company headquartered in New York City. Founded on Nobel-prize winning research, we launched our first commercial product in CNS in 2020 and received approval for an expanded indication in 2021. Currently celebrating our 22nd anniversary, we have a strong pipeline with projects in preclinical development stage through Phase III. We celebrate science, welcome curiosity, expect collaboration and demand integrity and respect in all we do, create and deliver.
“We deliver innovative treatments to improve the lives of individuals suffering from neuropsychiatric, neurologic and other disorders”.
224 articles about Intra-Cellular Therapies, Inc.
-
Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/10/2022
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Intra-Cellular Therapies to Host First Quarter 2022 Financial Results Conference Call and Webcast
5/3/2022
Intra-Cellular Therapies, Inc. announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, May 10, 2022, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2022.
-
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
4/25/2022
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), today announced that the U.S. Food and Drug Administration (FDA) approved two new dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg for patients with moderate or severe hepatic impairment (Child-Pugh class B or C).
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors
4/21/2022
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the appointment of E. Rene Salas to the Intra-Cellular Therapies Board of Directors.
-
Intra-Cellular Therapies to Present at the 21st Annual Needham Virtual Healthcare Conference
4/5/2022
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 11:00 am ET.
-
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
3/1/2022
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.
-
On Sunday, Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country.
-
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast
2/22/2022
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, March 1, 2022, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2021.
-
Intra-Cellular Therapies to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2/10/2022
Intra-Cellular Therapies, Inc. today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 8:40 am ET.
-
Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
1/7/2022
Intra-Cellular Therapies, Inc. announced the completion of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share.
-
Intra-Cellular Therapies Prices Public Offering of Common Stock - Jan 05, 2022
1/5/2022
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced the pricing of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share.
-
Intra-Cellular Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/3/2022
Intra-Cellular Therapies, Inc. announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 7:30 am ET.
-
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
12/20/2021
Intra-Cellular Therapies, Inc. today announced that the U.S. Food and Drug Administration approved CAPLYTA for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate.
-
Richard Lerner, who played a significant role in shaping both Scripps Research and the San Diego life sciences ecosystem and developing AbbVie’s blockbuster drug Humira, died Dec. 2.
-
Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/9/2021
Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-
Intra-Cellular Therapies to Host Third Quarter 2021 Financial Results Conference Call and Webcast
11/2/2021
Intra-Cellular Therapies, Inc. today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, November 9, 2021, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2021.
-
Intra-Cellular Therapies to Host a Virtual Event to Feature Highlights of Several of its Development Programs
10/8/2021
Virtual event to include discussions on our lumateperone, ITI-1284, PDE1 inhibitors and ITI-333 platforms Webcast scheduled for Wednesday, Oct. 20 from 12:30 to 3:30 p.m. ET
-
It was a busy week for clinical trial news. Here’s a look.
-
Intra-Cellular Therapies Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry
9/27/2021
Intra-Cellular Therapies, Inc. today announced the publication of the results from its lumateperone monotherapy Phase 3 clinical trial (ITI-007-404).